CHFR promoter methylation of ctDNA was found to be a negative prognostic factor for RFS in resectable Stage IV CRC in this study (#2) while that of cancer tissue gave a favorable PFS in advanced or metastatic CRC who underwent systemic chemotherapy with irinotecan-based regimen in Research #1. This evidence concerns the gene CHFR and colorectal carcinoma.